AzTrials
AzTrials

Juxtarenal Aortic AneurysmNCT04773223

Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment

An observational study of Juxtarenal Aortic Aneurysm and Pararenal Aneurysm, run by Clinical Centre of Serbia at 1 site in Serbia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Open surgery and complex EVAR due to AAA
Type of treatment
Surgery or procedure
How many people
925 participants
Where
1 siteSerbia
Study dates
1 Jan 2011to 1 Jan 2022
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients with juxta/pararenal abdominal aortic aneurysm (AAA) undergoing either open surgery or complex endovascular repair. The definition of the juxtarenal AAA will include those with a short neck (less than 1cm). The definition of the pararenal AAA will include those where renal arteries originate from the aneurysm itself.

Who may be able to join

  • All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2022
  • All management strategies will be included (endovascular and open)

Who cannot join

  • Patients who are pregnant
  • Patients who are under 18 years of age
  • Patients who have ruptured AAA
  • Patients with thoracoabdominal aortic aneurysm (ThAAA)
  • Patients who have a mycotic AAA
  • Patients with connective tissue disorder

Trial locations and contacts

1 site in 1 country.

Serbia1 site
  • Clinical Center of Serbia

    Belgrade, 11000

Other trials in Serbia

About this study

Official title: Comparison of Endovascular and Open Repair of Juxta- and Pararenal Abdominal Aortic Aneurysm on Short- and Long-term Clinical Outcomes

Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR).

Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA.

Read more

Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities.

Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.

Read the detailed description

Background Endovascular abdominal aortic aneurysm repair (EVAR) has gained widespread acceptance in the treatment of patients with abdominal aortic aneurysms (AAA). Prospective randomized trials (RCTs) have demonstrated several short-term advantages over open repair such as less blood loss, operative time, hospital stay, morbidity, and mortality. The applicability of EVAR is limited by the presence of inadequate neck or involvement of the visceral arteries. Thus consequently open AAA repair is now being performed primarily for complex aortic anatomies, such as juxtarenal and pararenal aneurysms. Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate and low morbidity and mortality with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Vascular surgeons are therefore left with a paucity of data to guide decision-making.

Study objectives:

  1. Primary aim: Compare Kaplan-Meier freedom from aortic related reintervention and all-cause mortality rate between endovascular and open repair group Primary endpoint: Kaplan-Meier survival rate and Kaplan-Meier aortic related reintervention rate after the patient recruitment ends
  2. Secondary aim: compare short term outcomes in terms of 30-day complications rate, especially acute kidney injury according to the RIFLE criteria Secondary endpoint: 30-day complications rate, especially acute kidney injury according to the RIFLE criteria

Inclusion criteria:

  • All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2021
  • All management strategies will be included (endovascular and open)

Exclusion criteria:

  • Patients who are pregnant
  • Patients who are under 18 years of age
  • Patients who have ruptured AAA
  • Patients with thoracoabdominal aortic aneurysm (ThAAA)
  • Patients who have a mycotic AAA
  • Patients with connective tissue disorder

Sample size To ensure sufficient statistical power to answer hypothetical questions, approximately 700 subjects will be entered into the database. Aortic-related reintervention rate is the primary endpoint being used to calculate the sample size. Assuming a difference of 7% in the late reintervention rate between endovascular and open repair, 221 patients would be required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (endovascular versus open), assuming a 20% rate of missing data, a total N of 550 patients is required.

Research Design

This is a prospective study including patients treated for juxta- and pararenal AAA from 2011 through 2021 treated at six different vascular surgery centers:

  1. Clinic for Vascular and Endovascular Surgery, Belgrade, Serbia
  2. Department of Vascular Surgery, Policlinico S. Orsola-Malpighi, Bologna, Italy
  3. Department of Vascular Surgery, San Raffaele Hospital, Milan, Italy
  4. Department of Vascular Surgery, Dijklander Ziekenhuis, Hoorn, Netherlands
  5. Department of Vascular Surgery, Amsterdam University Hospital, Amsterdam, Netherlands
  6. Department of Vascular Surgery, Helsinki Unversity Hospital, Helsinki, Finland

Procedures Involved The study does not involve any patient contact and will not impact the care that patients receive. Data regarding the patients will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, and comorbidities, diagnostic imaging information, laboratory data, surgical procedure information, complications of the surgery, and outcomes.

Multi-Institutional research After the data has been collected at a participating institution, the data will be transmitted to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/Clinical Center of Serbia/Medical Faculty, University of Belgrade.

Risks to Subjects As this is a prospective observational study, there is no potential for physical risks to subjects. There is a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information.

Potential Benefits to Subjects There is no direct benefit to the subjects. However, future patients with juxta- and pararenal AAA may benefit from improved care as a result of this study.

Statistics and Data Analysis Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and were compared using the chi-square test or Fisher exact test. Propensity score analysis will be performed by matching endovascular to open surgery group in a 1:1 ratio controlling for demographics, baseline comorbidities, and AAA parameters. Differences will be considered statistically significant at p < 0.05. The cumulative incidences of all-cause mortality and aortic-related complications will be estimated using the Kaplan-Meier method. Differences between curves will be tested using the log-rank test. Analyses will be done with SPSS software, version 20.0 (SPSS, Chicago, IL, USA).

Conflict of Interest The investigators have no conflict of interest to report.

Funding Source There are no plans to apply for grants or additional funding. No funding is required for the completion of this study.

Publication Plan All research personnel listed on this protocol will be eligible for authorship in any resulting abstracts and publications in accordance with the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.

Being tested
Open surgery and complex EVAR due to AAA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Open surgery and complex EVAR due to AAAProcedure or surgery

    There will be two cohorts:

    1. Patient undergoing open surgery
    2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)
Study groups in NCT04773223
Study groupRoleWhat they receive
Open surgery groupPatients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
Receives: Procedure: Open surgery and complex EVAR due to AAA
Endovascular groupPatients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
Receives: Procedure: Open surgery and complex EVAR due to AAA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Aortic Related Reintervention.

    In open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.

    Measured: through study completion, an average of 7 year

  2. All-cause Mortality

    Any cause of mortality duing follow-up period

    Measured: through study completion, an average of 7 year

Secondary outcomes (1)
  1. 30-day Acute Kidney Injury

    Acute kidney injury was defined using RIFFLE criteria.

    Measured: 30-day acute kidney injury

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Feb 2021
  2. Study start1 Jan 2011
  3. Primary completion1 Jan 2022
  4. Study completion1 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
925 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04773223
Sponsor's protocol ID
Complex AAA surgery
Status last verified
Feb 2024
First submitted
20 Feb 2021
Last updated
22 Jul 2024
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: This will be not available freely online, but on the request.

Publications

  • Tinelli G, Crea MA, de Waure C, Di Tanna GL, Becquemin JP, Sobocinski J, Snider F, Haulon S. A propensity-matched comparison of fenestrated endovascular aneurysm repair and open surgical repair of pararenal and paravisceral aortic aneurysms. J Vasc Surg. 2018 Sep;68(3):659-668. doi: 10.1016/j.jvs.2017.12.060. Epub 2018 Mar 22.

    PubMed 29576405
  • Raux M, Patel VI, Cochennec F, Mukhopadhyay S, Desgranges P, Cambria RP, Becquemin JP, LaMuraglia GM. A propensity-matched comparison of outcomes for fenestrated endovascular aneurysm repair and open surgical repair of complex abdominal aortic aneurysms. J Vasc Surg. 2014 Oct;60(4):858-63; discussion 863-4. doi: 10.1016/j.jvs.2014.04.011. Epub 2014 May 15.

    PubMed 24835042
  • Roy IN, Millen AM, Jones SM, Vallabhaneni SR, Scurr JRH, McWilliams RG, Brennan JA, Fisher RK. Long-term follow-up of fenestrated endovascular repair for juxtarenal aortic aneurysm. Br J Surg. 2017 Jul;104(8):1020-1027. doi: 10.1002/bjs.10524. Epub 2017 Apr 12.

    PubMed 28401533
  • Ferrante AM, Moscato U, Colacchio EC, Snider F. Results after elective open repair of pararenal abdominal aortic aneurysms. J Vasc Surg. 2016 Jun;63(6):1443-50. doi: 10.1016/j.jvs.2015.12.034. Epub 2016 Mar 16.

    PubMed 26994948
  • Zlatanovic P, Davidovic L, Mascia D, Ancetti S, Yeung KK, Jongkind V, Viitala H, Venermo M, Wiersema A, Chiesa R, Gargiulo M. Acute kidney injury in patients undergoing endovascular or open repair of juxtarenal or pararenal aortic aneurysms. J Vasc Surg. 2024 Jun;79(6):1347-1359.e3. doi: 10.1016/j.jvs.2024.02.021. Epub 2024 Feb 22.

    PubMed 38395093

Questions about this trial

What is this clinical trial studying?

An observational study of Juxtarenal Aortic Aneurysm and Pararenal Aneurysm, run by Clinical Centre of Serbia at 1 site in Serbia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Serbia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Jul 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Aortic Related Reintervention. (time frame: through study completion, an average of 7 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04773223, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in